BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, Ye L, Sundy JS, Besuyen R, Meuleners L, Stanislavchuk M, Spindler AJ, Greenwald M, Alten R, Genovese MC. Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. J Rheumatol 2021;48:1230-8. [PMID: 33526618 DOI: 10.3899/jrheum.201183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Casal-dominguez M, Pinal-fernandez I, Mammen AL. Inhibiting Interferon Pathways in Dermatomyositis: Rationale and Preliminary Evidence. Curr Treat Options in Rheum 2021;7:258-71. [DOI: 10.1007/s40674-021-00182-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Prasad P, Verma S, Surbhi, Ganguly NK, Chaturvedi V, Mittal SA. Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem 2022. [PMID: 35725992 DOI: 10.1007/s11010-022-04492-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese MC, Jiang D, Chen K, Bartok B, Jahreis A, Besuyen R, Burmester GR, Gottenberg JE. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis 2021:annrheumdis-2021-221051. [PMID: 34740884 DOI: 10.1136/annrheumdis-2021-221051] [Reference Citation Analysis]
4 D'Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis 2021:jjab206. [PMID: 34791103 DOI: 10.1093/ecco-jcc/jjab206] [Reference Citation Analysis]
5 Hanzel J, Hulshoff MS, Grootjans J, D'Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol 2022. [PMID: 35477319 DOI: 10.1080/1744666X.2022.2069562] [Reference Citation Analysis]
6 Atzeni F, Popa CD, Nucera V, Nurmohamed MT. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. Expert Review of Clinical Immunology. [DOI: 10.1080/1744666x.2022.2039630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Benucci M, Damiani A, Infantino M, Manfredi M, Lari B, Grossi V, Gobbi FL, Sarzi-Puttini P. Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted. Pharmacol Res 2022;183:106359. [PMID: 35907434 DOI: 10.1016/j.phrs.2022.106359] [Reference Citation Analysis]
8 Palominos PE, Lineburger IB, Xavier RM. Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis. Expert Opin Emerg Drugs 2021;26:303-21. [PMID: 34365877 DOI: 10.1080/14728214.2021.1964472] [Reference Citation Analysis]
9 Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol 2021;:1-9. [PMID: 34860621 DOI: 10.1080/1744666X.2022.2014323] [Reference Citation Analysis]
10 Minnis-lyons SE, Aiken Z, Chow S, Din S. Managing IBD in patients with previous cancers. Frontline Gastroenterol 2022;13:e44-50. [DOI: 10.1136/flgastro-2022-102187] [Reference Citation Analysis]
11 Namour F, Anderson K, Nelson C, Tasset C. Filgotinib: A Clinical Pharmacology Review. Clin Pharmacokinet 2022. [PMID: 35637376 DOI: 10.1007/s40262-022-01129-y] [Reference Citation Analysis]